A shadow market for unlicensed slimming drugs is propelled by social media fitness personalities and sellers on messaging platforms, according to new investigations.
Investigational Drug Gaining Popularity Online
The experimental drug, which is still in clinical trials, is being advertised by online personalities for its supposed weight-reducing properties. Followers are urged to message these accounts privately for supplier links, while also obtaining promotional offers.
Thriving Trade on Messaging Platforms
Separately, a robust market exists on Telegram, where groups with thousands of members share “before and after” images, injection guides and claims of next-day British shipping. Vendors market the substance there before directing customers to other platforms for purchases.
Understanding The Experimental Drug
Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could assist individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Medical Professionals Express Concerns
However, physicians and chemists have warned that the distribution of what remains an unlicensed medication in the United Kingdom is worrisome and could lead to users administering products of unknown origin.
Several professionals said the popularity for retatrutide could be connected to the rising cost of licensed slimming treatments such as Mounjaro.
Regulatory Position and Implementation
Selling retatrutide on social media or messaging apps is illegal in the UK, as it is an unapproved medication that must not be marketed or distributed for human use under the British medical regulations.
Some content creators try to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but promotion and distribution can still breach pharmaceutical, marketing, and consumer laws, risking penalties, legal action or imprisonment.
Platform Response and Material Elimination
According to the social media company, the service has removed problematic content and banned associated hashtags and query recommendations. The organization said it was committed to maintaining the service secure and investing in enhancing compliance measures.
Digital Marketplace Operations
Research also found communities with up to 9,000 participants marketing the experimental drug using the platform's built-in discovery tool, which functions like a public directory. Typing “retatrutide” instantly brings up groups with thousands of members, populated with photos of slimming results, positive reviews and detailed guides for preparing or injecting at home.
Within minutes of joining one community, a vendor posted contact information, where most purchases take place. The vendor sent an guidebook and guaranteed delivery within 48 hours. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. None inquired about weight, medical conditions or past usage.
Product Details and Costs
Within these communities, posts show dark colored packages with postal service labels, stating to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Customers can select between powder vials, prepared at home with sterile water, or pre-filled injectors usually sold at £160 for 20mg. When questioned how long a injector should last, vendors give contradictory responses ranging from a several days to “depends on your body”.
Platform Oversight and Safety Actions
A representative for Telegram said it regularly moderated harmful material on its service including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Medical Professional Cautions
“People are injecting substances they can’t verify. Even if the science behind this drug is valid, these digital versions may not contain what they advertise,” stated Jason Murphy, the director of pharmacy at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the surge in demand to recent price rises for authorized slimming medications such as Mounjaro. “With costs increasing, individuals are using online platforms. But fake treatments are highly risky. You can’t be certain what’s contained or whether the environment they were produced in was clean,” she explained.
Her team has previously encountered patients injured by personal administration from unconfirmed suppliers. “We recognize the frustration, but buying from messaging apps or WhatsApp is gambling with your health,” stated the doctor. “These materials could be impure or improperly measured.”
Producer Statement
A spokesperson from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or approved by any government authority globally. “Consequently at this time no one can market [it] for human use,” they explained, noting that any product “falsely representing itself as a Lilly experimental product not yet authorized … may subject users to possibly significant medical dangers”.
